BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Olutasidenib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Olutasidenib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07411586-2857@assetmemo.bio
DTSTAMP:20261121T010124Z
DTSTART;VALUE=DATE:20270114
DTEND;VALUE=DATE:20270115
SUMMARY:Olutasidenib: Phase 1 readout est. (NCT07411586)
DESCRIPTION:Olutasidenib\, phase 1\, Acute Myeloid Leukemia.\nStudy: Phase 
 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acu
 te Myeloid Leukemia\nEstimated primary completion: 14 January 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/olutasidenib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07411586
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06543381-2857@assetmemo.bio
DTSTAMP:20261121T010124Z
DTSTART;VALUE=DATE:20270205
DTEND;VALUE=DATE:20270206
SUMMARY:Olutasidenib: Phase 1 readout est. (NCT06543381)
DESCRIPTION:Olutasidenib\, phase 1\, Acute Myeloid Leukemia.\nStudy: Olutas
 idenib for the Treatment of Patients With IDH1 Mutated AML\, MDS or CMML A
 fter Donor Hematopoietic Cell Transplant\nEstimated primary completion: 5 
 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olutas
 idenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06543381
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486713-2857@assetmemo.bio
DTSTAMP:20261121T010124Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Olutasidenib: Phase 4 readout est. (NCT07486713)
DESCRIPTION:Olutasidenib\, phase 4\, Acute Myeloid Leukemia.\nStudy: Olutas
 idenib DDI Study in Patients With IDH1 Mutation Positive Malignancies\nEst
 imated primary completion: 30 April 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/olutasidenib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07486713
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07032727-2857@assetmemo.bio
DTSTAMP:20261121T010124Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Olutasidenib: Phase 2 readout est. (NCT07032727)
DESCRIPTION:Olutasidenib\, phase 2.\nStudy: Olutasidenib Combined With Co-t
 argeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancie
 s Harboring Activated Signaling Pathway Mutations\nEstimated primary compl
 etion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/o
 lutasidenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07032727
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06445959-2857@assetmemo.bio
DTSTAMP:20261121T010124Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Olutasidenib: Phase 1/2 readout est. (NCT06445959)
DESCRIPTION:Olutasidenib\, phase 1/2.\nStudy: Phase 1b/2 Study of Decitabin
 e and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Ol
 utasidenib\nEstimated primary completion: 30 June 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/olutasidenib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06445959
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06566742-2857@assetmemo.bio
DTSTAMP:20261121T010124Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Olutasidenib: Phase 2 readout est. (NCT06566742)
DESCRIPTION:Olutasidenib\, phase 2.\nStudy: A Phase 2 Study Evaluating Olut
 asidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Si
 gnificance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic
  Leukemia.\nEstimated primary completion: 31 August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/olutasidenib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06566742
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07304011-2857@assetmemo.bio
DTSTAMP:20261121T010124Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Olutasidenib: Phase 2 readout est. (NCT07304011)
DESCRIPTION:Olutasidenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Olutas
 idenib With Azacitidine Followed by Olutasidenib Maintenance for the Treat
 ment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatme
 nt With Venetoclax Plus a Hypomethylating Agent\nEstimated primary complet
 ion: 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /olutasidenib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07304011
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06668584-2857@assetmemo.bio
DTSTAMP:20261121T010124Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Olutasidenib: Phase 2 readout est. (NCT06668584)
DESCRIPTION:Olutasidenib\, phase 2.\nStudy: A Phase II Open-label Study of 
 Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mu
 tated Myeloid Malignancies\nEstimated primary completion: 31 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/olutasidenib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06668584
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07471841-2857@assetmemo.bio
DTSTAMP:20261121T010124Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Olutasidenib: Phase 2 readout est. (NCT07471841)
DESCRIPTION:Olutasidenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Olutas
 idenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received 
 Venetoclax\nEstimated primary completion: June 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/olutasidenib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07471841
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06782542-2857@assetmemo.bio
DTSTAMP:20261121T010124Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Olutasidenib: Phase 2 readout est. (NCT06782542)
DESCRIPTION:Olutasidenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Olutas
 idenib\, Venetoclax\, and Azacitidine in IDH1 Mutated Newly Diagnosed Acut
 e Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy\
 nEstimated primary completion: 31 March 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/olutasidenib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06782542
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564390-2857@assetmemo.bio
DTSTAMP:20261121T010124Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Olutasidenib: Phase 2 readout est. (NCT05564390)
DESCRIPTION:Olutasidenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: MYELOM
 ATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatmen
 t Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screen
 ing Trial)\nEstimated primary completion: 15 May 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/olutasidenib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05564390
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06161974-2857@assetmemo.bio
DTSTAMP:20261121T010124Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Olutasidenib: Phase 2 readout est. (NCT06161974)
DESCRIPTION:Olutasidenib\, phase 2\, Glioma.\nStudy: Study of Olutasidenib 
 and Temozolomide in HGG\nEstimated primary completion: June 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/olutasidenib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06161974
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07153497-2857@assetmemo.bio
DTSTAMP:20261121T010124Z
DTSTART;VALUE=DATE:20300426
DTEND;VALUE=DATE:20300427
SUMMARY:Olutasidenib: Phase 2 readout est. (NCT07153497)
DESCRIPTION:Olutasidenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Testin
 g the Use of an IDH1 Inhibitor\, Olutasidenib\, in Acute Myeloid Leukemia 
 Added to ASTX727 and Venetoclax\; in High-Risk MDS Added to ASTX727\; and 
 Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)\nEstimated primary
  completion: 26 April 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/olutasidenib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07153497
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604064-2857@assetmemo.bio
DTSTAMP:20261121T010124Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Olutasidenib: Phase 2 readout est. (NCT07604064)
DESCRIPTION:Olutasidenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Clin
 ical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia\nEstima
 ted primary completion: September 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/olutasidenib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07604064
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
